Mucociliary dysfunction in COPD: Effect of current pharmacotherapeutic options

Pulmonary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2005, Pages 1-8

  Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti cholinergic; COPD; LABA; Mucociliary

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; ETANERCEPT; EXPECTORANT AGENT; FORMOTEROL; GEFITINIB; GLUCOCORTICOID; GUAIFENESIN; INFLIXIMAB; IPRATROPIUM BROMIDE; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; MUCIN; MUCOLYTIC AGENT; OXITROPIUM BROMIDE; ROFLUMILAST; SALBUTAMOL; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIATED EPITHELIUM; CLINICAL TRIAL; DRUG TARGETING; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; RHEUMATOID ARTHRITIS;

EID: 10644240946     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.08.001     Document Type: Article

References (84)

1. Rogers DF. Overview of airway mucus clearance. In: Rubin BK, van der Schans CP, editors. Therapy for mucus-clearance disorders: lung biology in health and disease. Lenfant C, editor. vol. 188. New York: Marcel Dekker; 2004 [in press].
2. D.M. Mannino COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity Chest 121 2002 121S 126S
3. C.J. Murray, and A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: global burden of Disease Study Lancet 349 1997 1498 1504
4. S. Rennard, M. Decramer, and P.M. Calverley Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey Eur Respir J 20 2002 799 805
5. National Heart, Lung and Blood Institute, World Health Organisation Global initiative for chronic obstructive lung disease Publication no. 2701 2001 National Institutes of Health Bethesda
6. D.D. Sin, F.A. McAlister, S.F. Man, and N.R. Anthonisen Contemporary management of chronic obstructive pulmonary disease: scientific review JAMA 290 2003 2301 2312
7. P.J. Barnes COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 4 2004 263 272
8. S.V. Culpitt, and D.F. Rogers Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease Expert Opin Pharmacother 1 2000 1007 1020
9. L.E. Donnelly, and D.F. Rogers Therapy for COPD in the 21st Century Drugs 63 2003 1973 1998
10. L.E. Donnelly, and D.F. Rogers Antiproteases and retinoids for treatment of COPD Expert Opin Ther Patents 13 2003 1345 1372
11. G.C. Smaldone, W.M. Foster, T.G. O'Riordan, M.S. Messina, R.J. Perry, and E.G. Langenback Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease Chest 103 1993 1390 1396
12. G.L. Snider, L.J. Faling, and S.I. Rennard Chronic bronchitis and emphysema J.F. Murray J.A. Nadel Textbook of respiratory medicine 1994 W.B. Saunders Philadelphia 1331 1397
13. T. Aikawa, S. Shimura, H. Sasaki, T. Takishima, H. Yaegashi, and T. Takahashi Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease Am Rev Respir Dis 140 1989 477 482
14. M.T. Lopez-Vidriero, and L. Reid Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases Am Rev Respir Dis 117 1978 465 477
15. K.R. Bhaskar, D.D. O'Sullivan, H. Opaskar-Hincman, L.M. Reid, and S.J. Coles Density gradient analysis of secretions produced in vitro by human and canine airway mucosa: identification of lipids and proteoglycans in such secretions Exp Lung Res 10 1986 401 422
16. D.F. Rogers Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy Monaldi Arch Chest Dis 55 2000 324 332
17. J. Vestbo, E. Prescott, and P. Lange Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group Am J Respir Crit Care Med 153 1996 1530 1535
18. E. Prescott, P. Lange, and J. Vestbo Chronic mucus hypersecretion in COPD and death from pulmonary infection Eur Respir J 8 1995 1333 1338
19. L. Melton Does mucus hypersecretion matter in airway disease? Lancet 359 2002 1924
20. J.B. Mullen, J.L. Wright, B.R. Wiggs, P.D. Pare, and J.C. Hogg Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function Thorax 42 1987 843 848
21. A. Wanner The role of mucus in chronic obstructive pulmonary disease Chest 97 1990 11S 15S
22. A. Wanner Clinical aspects of mucociliary transport Am Rev Respir Dis 116 1977 73 125
23. E.M. McDowell, L.A. Barrett, C.C. Harris, and B.F. Trump Abnormal cilia in human bronchial epithelium Arch Pathol Lab Med 100 1976 429 436
24. S. Kim, and J.A. Nadel Role of neutrophils in mucus hypersecretion in COPD and implications for therapy Treat Respir Med 3 2004 147 159
25. W. MacNee, and I. Rahman Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 7 2001 55 62
26. K. Takeyama, K. Dabbagh, S.J. Jeong, T. Dao-Pick, I.F. Ueki, and J.A. Nadel Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils J Immunol 164 2000 1546 1552
27. J.R. Davies, H.W. Hovenberg, and C.J. Linden Mucins in airway secretions from healthy and chronic bronchitic subjects Biochem J 313 1996 431 439
28. D.J. Thornton, I. Carlstedt, M. Howard, P.L. Devine, M.R. Price, and J.K. Sheehan Respiratory mucins: identification of core proteins and glycoforms Biochem J 316 1996 967 975
29. S. Sethi Bacterial infection and the pathogenesis of COPD Chest 117 2000 286S 291S
30. L.M. Fabbri, and S.S. Hurd Global Strategy for the diagnosis, management and prevention of COPD: 2003 update Eur Respir J 22 2003 1 2
31. D.F. Rogers Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 11 2002 15 35
32. B. Disse Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases Novartis Found Symp 248 2002 254 272
33. M. Salathe, T.G. O'Riordan, and A. Wanner Treatment of mucociliary dysfunction Chest 110 1996 1048 1057
34. P.J. Poole, and P.N. Black Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review BMJ 322 2001 1271 1274
35. W.M. Foster, E.G. Langenback, and E.H. Bergofsky Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects Ann Occup Hyg 26 1982 227 244
36. D.B. Yeates, D.M. Spektor, and B.R. Pitt Effect of orally administered orciprenaline on tracheobronchial mucociliary clearance Eur J Respir Dis 69 1986 100 108
37. B. Mossberg, K. Strandberg, K. Philipson, and P. Camner Tracheobronchial clearance in bronchial asthma: response to beta-adrenoceptor stimulation Scand J Respir Dis 57 1976 119 128
38. B. Mossberg, K. Strandberg, K. Philipson, and P. Camner Tracheobronchial clearance and beta-adrenoceptor stimulation in patients with chronic bronchitis Scand J Respir Dis 57 1976 281 289
39. W.D. Bennett Effect of beta-adrenergic agonists on mucociliary clearance J Allergy Clin Immunol 110 2002 S291 S297
40. J.L. Devalia, R.J. Sapsford, C. Rusznak, M.J. Toumbis, and R.J. Davies The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro Pulm Pharmacol 5 1992 257 263
41. J. Tamaoki, M. Kondo, and T. Takizawa Effect of cAMP on ciliary function in rabbit tracheal epithelial cells J Appl Physiol 66 1989 1035 1039
42. M. Salathe Effects of beta-agonists on airway epithelial cells J Allergy Clin Immunol 110 2002 S275 S281
43. R.J. Phipps, I.P. Williams, P.S. Richardson, J. Pell, R.J. Pack, and N. Wright Sympathomimetic drugs stimulate the output of secretory glycoproteins from human bronchi in vitro Clin Sci (Lond) 63 1982 23 28
44. A. Wanner Effects of methylxanthines on airway mucociliary function Am J Med 79 1985 16 21
45. R.J. Perry, and G.C. Smaldone Effect of bronchodilators on mucociliary clearance in normal adults J Aerosol Med 3 1990 187 196
46. D.A. Mahler, J.F. Donohue, and R.A. Barbee Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957 965
47. P.W. Jones, and T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283 1289
48. R. Aalbers, J. Ayres, and V. Backer Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur Respir J 19 2002 936 943
49. C. Chambers, B. Corrigan, and M. Newhouse Salmeterol speeds mucociliary transport in healthy subjects Am J Respir Crit Care Med 159 1999 A636 [abstr]
50. A. Hasani, N. Toms, J. O'Connor, J.P. Dilworth, and J.E. Agnew Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma Respir Med 97 2003 667 671
51. B. Melloni, and J. Germouty The influence of a new beta agonist: formoterol on mucociliary function Rev Mal Respir 9 1992 503 507
52. R.B. Dowling, C.F. Rayner, and A. Rutman Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa Am J Respir Crit Care Med 155 1997 327 336
53. R.B. Dowling, M. Johnson, P.J. Cole, and R. Wilson Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro Eur Respir J 11 1998 86 90
54. C. Coraux, C. Kileztky, and M. Polette Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist Am J Respir Cell Mol Biol 30 2004 605 612
55. P.K. Jeffery, P. Venge, M.J. Gizycki, I. Egerod, R. Dahl, and P. Faurschou Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study Eur Respir J 20 2002 1378 1385
56. T.G. Christensen, R. Breuer, L.J. Hornstra, E.C. Lucey, P.J. Stone, and G.L. Snider An ultrastructural study of the response of hamster bronchial epithelium to human neutrophil elastase Exp Lung Res 13 1987 279 297
57. 2-adrenergic agonists in COPD Chest 120 2001 258 270
58. B. Balbi, M. Majori, and S. Bertacco Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 117 2000 1633 1637
59. F. Yildiz, A.C. Kaur, and A. Ilgazli Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease Respiration 67 2000 71 76
60. K.L. Hattotuwa, M.J. Gizycki, T.W. Ansari, P.K. Jeffery, and N.C. Barnes The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study Am J Respir Crit Care Med 165 2002 1592 1596
61. P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial Br Med J 320 2000 1297 1303
62. P. Calverley, R. Pauwels, and J. Vestbo Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
63. W. Szafranski, A. Cukier, and A. Ramirez Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
64. R.B. Dowling, M. Johnson, P.J. Cole, and R. Wilson Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro Eur Respir J 14 1999 363 369
65. H. Kai, K. Yoshitake, and A. Hisatsune Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells Am J Physiol 271 1996 L484 L488
66. D.F. Rogers Pharmacological regulation of the neuronal control of airway mucus secretion Curr Opin Pharmacol 2 2002 249 255
67. P. Cammer, K. Strandberg, and K. Philipson Increased mucociliary transport by cholinergic stimulation Arch Environ Health 29 1974 220 224
68. L.A. Gatto Cholinergic and adrenergic stimulation of mucociliary transport in the rat trachea Respir Physiol 92 1993 209 217
69. J. Berger, R.E. Albert, K. Sanborn, and M. Lippmann Effects of atropine and methacholine on deposition and clearance of inhaled particles in the donkey J Toxicol Environ Health 4 1978 587 604
70. S.F. Abad, J. Novalbos, S.S. Gallego, and M.A. Galvez Mugica [Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors] Regulacion del tono bronquial en la enfermedad pulmonar obstructiva cronica (EPOC): papel de los receptores muscarinicos An Med Int 20 2003 201 205
71. F.R. Coulson, and A.D. Fryer Muscarinic acetylcholine receptors and airway diseases Pharmacol Ther 98 2003 59 69
72. J. Tamaoki, A. Chiyotani, E. Tagaya, N. Sakai, and K. Konno Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis Thorax 49 1994 545 548
73. D. Pavia, P.P. Sutton, M.T. Lopez-Vidriero, J.E. Agnew, and S.W. Clarke Drug effects on mucociliary function Eur J Respir Dis Suppl 128 1983 304 317
74. A. Hasani, N. Toms, D.D. Creer, J.E. Agnew, J.P. Dilworth, and M. Sarno Effect of inhaled tiotropium on tracheobronchial clearance in patients with COPD Eur Respir J 18 2001 P1678
75. S.J. Levine, P. Larivee, C. Logun, C.W. Angus, F.P. Ognibene, and J.H. Shelhamer Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells Am J Respir Cell Mol Biol 12 1995 196 204
76. J.A. Nadel, and P.R. Burgel The role of epidermal growth factor in mucus production Curr Opin Pharmacol 1 2001 254 258
77. M.A. Giembycz Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease Expert Opin Investig Drugs 10 2001 1361 1379
78. E. Gamble, D.C. Grootendorst, and C.E. Brightling Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease Am J Respir Crit Care Med 168 2003 976 982
79. G.F. Joos, K.O. De Swert, V. Schelfhout, and R.A. Pauwels The role of neural inflammation in asthma and chronic obstructive pulmonary disease Ann NY Acad Sci 992 2003 218 230
80. D.F. Rogers Tachykinin receptor antagonists for asthma and COPD Expert Opin Ther Patents 11 2001 1097 1121
81. Y. Li, L.D. Martin, G. Spizz, and K.B. Adler MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro J Biol Chem 276 2001 40982 40990
82. M. Singer, L.D. Martin, and B.B. Vargaftig A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma Nat Med 10 2004 193 196
83. H.P. Hauber, A. Tsicopoulos, B. Wallaert, S. Griffin, N.G. McElvaney, and P. Daigneault Expression of HCLCA1 in cystic fibrosis lungs is associated with mucus overproduction Eur Respir J 23 2004 846 850
84. Y. Zhou, M. Shapiro, Q. Dong, J. Louahed, C. Weiss, and S. Wan A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction Novartis Found Symp 248 2002 150 165